Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RenovoRx (RNXT) Research & Development (2024 - 2025)

RenovoRx's Research & Development history spans 2 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Research & Development rose 3.03% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $6.3 million, changed N/A, while the annual FY2024 figure was $6.0 million, 6.32% up from the prior year.
  • Research & Development for Q3 2025 was $1.7 million at RenovoRx, up from $1.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.7 million in Q3 2025 and bottomed at $1.3 million in Q1 2024.